EIKN (Eikon Therapeutics) Other Financing: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EIKN Eikon Therapeutics Inc EIKN
12 GF Score
Price $9.78
View Full Analysis

What is Eikon Therapeutics Other Financing?

Eikon Therapeutics EIKN -0.56% 12 Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus rates EIKN with a GF Score™ of 12/100.

Eikon Therapeutics's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

Eikon Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Eikon Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for Eikon Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eikon Therapeutics Other Financing Chart

Eikon Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Other Financing
0.00 0.00 0.00

Eikon Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
EIKN
12GF Score
Eikon Therapeutics Inc EIKN
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eikon Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
Eikon Therapeutics (EIKN) has a Other Financing of $0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Eikon Therapeutics and its competitors.
Is Eikon Therapeutics' Other Financing too high?
Eikon Therapeutics' current Other Financing is $0.00 Mil. Overall, Eikon Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Eikon Therapeutics' Other Financing compare to PRME and CRMD?
Eikon Therapeutics' Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Eikon Therapeutics and its competitors. Eikon Therapeutics's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eikon Therapeutics stock overvalued right now?
Eikon Therapeutics (EIKN) has a current Other Financing of $0.00 Mil. The current Other Financing is $0.00 Mil. Eikon Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Eikon Therapeutics (EIKN), the current Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eikon Therapeutics Business Description

Address 230 Harriet Tubman Way, Millbrae, CA, USA, 94030
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
12GF Score

Get the complete analysis for EIKN

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.78
Price